Literature DB >> 24011886

Effects of antipsychotic medications on appetite, weight, and insulin resistance.

Chao Deng1.   

Abstract

Although clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyramidal side effects, they have serious metabolic side effects such as substantial weight gain, intra-abdominal obesity, and type 2 diabetes mellitus. Given that most patients with mental disorders face chronic, even life-long, treatment with APDs, the risks of weight gain/obesity and other metabolic symptoms are major considerations for APD maintenance treatment. This review focuses on the effects of APDs on weight gain, appetite, insulin resistance, and glucose dysregulation, and the relevant underlying mechanisms that may be help to prevent and treat metabolic side effects caused by APD therapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antipsychotic; Appetite; Glucose dysregulation; Insulin resistance; Obesity; Weight gain

Mesh:

Substances:

Year:  2013        PMID: 24011886     DOI: 10.1016/j.ecl.2013.05.006

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  41 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Brain stem as a target site for the metabolic side effects of olanzapine.

Authors:  Imran J Anwar; Kayoko Miyata; Andrea Zsombok
Journal:  J Neurophysiol       Date:  2015-12-30       Impact factor: 2.714

3.  Insulin Stimulates S100B Secretion and These Proteins Antagonistically Modulate Brain Glucose Metabolism.

Authors:  Krista Minéia Wartchow; Ana Carolina Tramontina; Daniela F de Souza; Regina Biasibetti; Larissa D Bobermin; Carlos-Alberto Gonçalves
Journal:  Neurochem Res       Date:  2016-02-15       Impact factor: 3.996

4.  Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.

Authors:  Julie R Larsen; Louise Vedtofte; Mathilde S L Jakobsen; Hans R Jespersen; Michelle I Jakobsen; Camilla K Svensson; Kamuran Koyuncu; Ole Schjerning; Peter S Oturai; Andreas Kjaer; Jimmi Nielsen; Jens J Holst; Claus T Ekstrøm; Christoph U Correll; Tina Vilsbøll; Anders Fink-Jensen
Journal:  JAMA Psychiatry       Date:  2017-07-01       Impact factor: 21.596

5.  Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain.

Authors:  Alessandro Rimessi; Chiara Pavan; Elli Ioannidi; Federica Nigro; Claudia Morganti; Alberto Brugnoli; Francesco Longo; Chiara Gardin; Letizia Ferroni; Michele Morari; Vincenzo Vindigni; Barbara Zavan; Paolo Pinton
Journal:  Neuropsychopharmacology       Date:  2017-01-27       Impact factor: 7.853

Review 6.  Dopaminergic Pathways in Obesity-Associated Inflammation.

Authors:  Fernanda Leite; Laura Ribeiro
Journal:  J Neuroimmune Pharmacol       Date:  2019-07-17       Impact factor: 4.147

7.  Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia.

Authors:  Giuliana S Zuccoli; Caroline Brandão-Teles; Gabriela Maciel Vieira; Felipe V Gomes; Fernanda Crunfli
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

8.  Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain.

Authors:  Rizaldy C Zapata; Olivia Osborn
Journal:  Physiol Behav       Date:  2020-03-07

Review 9.  Diabetes and Schizophrenia.

Authors:  Jaana Suvisaari; Jaakko Keinänen; Saana Eskelinen; Outi Mantere
Journal:  Curr Diab Rep       Date:  2016-02       Impact factor: 4.810

Review 10.  The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

Authors:  Per Damkier; Poul Videbech
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.